HOLOGIC INCの売上高は？

HOLOGIC INCの2025年度の売上高は$4.1Bです（前年比+1.7%）。

HOLOGIC INCの営業利益は？

HOLOGIC INCの2025年度の営業利益は$714Mです（前年比-19.1%）。

HOLOGIC INCの純利益は？

HOLOGIC INCの2025年度の純利益は$566Mです（前年比-28.3%）。

HOLOGIC INCのROEは？

HOLOGIC INCの2025年度のROE（自己資本利益率）は11.2%です。

企業一覧に戻る

HOLOGIC INC（HOLX）の決算・業績分析

HOLOGIC INCの2025年有価証券報告書をAI分析。売上高$4.1B(+1.7%)。営業利益$714M。Health Care。

SUMMARY — 業績サマリー

HOLOGIC INCの2025年度業績サマリー

HOLOGIC INC（証券コード: HOLX）の2025年度決算・業績分析。売上高は$4.1B（前年比+1.7%）。営業利益は$714M（前年比-19.1%）。純利益は$566M（前年比-28.3%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。

HOLOGIC INCの2024年度注目ポイント

※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。

Revenue declined 13.7% YoY to $4.9B (XBRL), driven by reduced demand in key product lines.
Operating income fell 33.9% YoY to $1.6B (XBRL), despite strong gross margins of 61.6% (XBRL).
Strong liquidity with $2.7B cash (XBRL) and net debt of -$191M (-0.1x EBITDA) (XBRL).
Share repurchases totaled $542M (XBRL), reflecting confidence in long-term value.

HOLOGIC INCの売上高変化の要因

•FY2024 revenue of $4.9B (XBRL) reflects a 13.7% YoY decline, with historical data showing a peak of $5.6B in FY2023 (XBRL). The decline may be attributed to reduced demand for certain products, though specific segment drivers are not detailed (10-K). Over the past five years, revenue grew at a 4.6% CAGR (XBRL). FY2025 guidance is $4.0B (XBRL).

HOLOGIC INCの営業利益変化の要因

•Gross profit was $3.0B (XBRL) with a 61.6% margin (XBRL). Operating income fell 33.9% YoY to $1.6B (XBRL), and net income declined 30.4% YoY to $1.3B (XBRL). Operating margin was 33.7% (XBRL), and net margin was 26.8% (XBRL). EBITDA was $1.7B (35.6% of revenue) (XBRL).

HOLOGIC INCの事業リスクと対応

Intense competition with potential for superior or cheaper products (10-K).

Challenges in product development, including regulatory and market acceptance risks (10-K).

Declining demand for COVID-19 assays impacting revenue (10-K).

Evolving regulatory risks around AI in healthcare products (10-K).

Uncertainty in market development for new products (10-K).

Acquisition of Endomag in July 2024 (10-K).

HOLOGIC INCの今後の見通し・業績予想

Management provided FY2025 revenue guidance of $4.0B (XBRL). Key trends include the impact of the post-pandemic environment and new product launches (e.g., molecular assays) (10-K).

HOLOGIC INCの事業内容

Hologic Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical devices focused on women's health (10-K). Revenue is generated through product sales (e.g., diagnostic assays, imaging systems) and service revenues from its CLIA-certified laboratory (10-K). Key segments include Diagnostics (molecular assays, ThinPrep cytology), Breast Health (3D mammography, AI imaging), GYN Surgical (hysteroscopic devices), and Skeletal Health (DXA bone density systems) (10-K). Competitive advantages include advanced instrumentation systems (e.g., Panther Fusion), AI-driven imaging solutions, and a broad portfolio of women's health products (10-K). R&D expense was $283M in FY2024 (XBRL).

HOLOGIC INCのAI業績分析レポート（2024年度）

Hologic Inc. (HOLX) FY2024 Annual Report Analysis

Highlights

•Revenue declined 13.7% YoY to $4.9B (XBRL), driven by reduced demand in key product lines.

•Operating income fell 33.9% YoY to $1.6B (XBRL), despite strong gross margins of 61.6% (XBRL).

•Strong liquidity with $2.7B cash (XBRL) and net debt of -$191M (-0.1x EBITDA) (XBRL).

•Share repurchases totaled $542M (XBRL), reflecting confidence in long-term value.

Business Overview

Revenue Analysis

FY2024 revenue of $4.9B (XBRL) reflects a 13.7% YoY decline, with historical data showing a peak of $5.6B in FY2023 (XBRL). The decline may be attributed to reduced demand for certain products, though specific segment drivers are not detailed (10-K). Over the past five years, revenue grew at a 4.6% CAGR (XBRL). FY2025 guidance is $4.0B (XBRL).

Profitability Analysis

Gross profit was $3.0B (XBRL) with a 61.6% margin (XBRL). Operating income fell 33.9% YoY to $1.6B (XBRL), and net income declined 30.4% YoY to $1.3B (XBRL). Operating margin was 33.7% (XBRL), and net margin was 26.8% (XBRL). EBITDA was $1.7B (35.6% of revenue) (XBRL).

Balance Sheet Analysis

Total assets were $9.1B (XBRL), with $5.0B in total equity (XBRL). Cash was $2.7B (XBRL), and long-term debt was $2.5B (XBRL). Net debt was -$191M (-0.1x EBITDA) (XBRL). Equity ratio was 55.3% (XBRL), and current ratio was 3.47x (XBRL). ROE was 25.9% (XBRL), and ROA was 14.3% (XBRL).

Cash Flow Analysis

Operating cash flow was $2.1B (XBRL), with free cash flow of $2.1B (XBRL) after $71M in CapEx (XBRL). Investing cash flow was -$206M (XBRL), and financing cash flow was -$756M (XBRL), driven by $542M in share repurchases (XBRL). No dividends were mentioned (N/A).

Working Capital Analysis

Cash conversion cycle (CCC) was 80 days (XBRL), with receivables days at 47 days (XBRL), inventory days at 46 days (XBRL), and payables days at 13 days (XBRL).

Risks

•Intense competition with potential for superior or cheaper products (10-K).

•Challenges in product development, including regulatory and market acceptance risks (10-K).

•Declining demand for COVID-19 assays impacting revenue (10-K).

•Evolving regulatory risks around AI in healthcare products (10-K).

•Uncertainty in market development for new products (10-K).

•Acquisition of Endomag in July 2024 (10-K).

Outlook